Pharmacokinetics and Tolerability of Factor XIII Concentrates Prepared from Human Placenta or Plasma: a Crossover Randomised Study

Summary

The pharmacokinetics and tolerability of factor XIII (FXIII) from plasma were compared with those of FXIII from placenta in a randomised, double-blind, crossover study involving 13 patients with congenital FXIII deficiency. Both FXIII activity and FXIII antigen were monitored. No difference was seen in the mean half-lives of the two preparations (9.3 days and 9.1 days for plasma and placenta FXIII activity, respectively). Response was similar for both preparations, but was slightly greater for FXIII from plasma.

Similar results were found for recovery (65% vs 60%). The area under the data completed by extrapolation was significantly higher for FXIII from plasma. No differences between preparations in terms of efficacy or tolerability were observed. It can be concluded that treatment with FXIII concentrate from plasma is as efficient as with FXIII concentrate from placenta in terms of recovery and half-life. Both preparations were equivalent in terms of safety during the observation period. With the administration of monthly injections of approximately 30 U/kg serious bleeding events were prevented and no other serious adverse events occurred.

• References

• 1 Israels ED, Paraskcvas F, Israels LG. Immunological studies of coagulation factor XIII. J Clin Invest 1973; 32: 2398-2403
• 2 Bohn II, Becker W, Trobisch II. Die molekulare Struktur der fibrinstabilisierenden Faktoren des Mensehen. II. Vergleiehcnde immunologisehe Untersuehungen von Faktor-XIII-Mangelplasmen und Normalplasma Blut 1973; 26: 303-311
• 3 Duekert F. Documentation of the plasma factor XIII deficiency in man. Ann NY AeadSei 1972; 202: 190-199
• 4 Berliner SH, Lusky A, Zivelin A, Modan M. Hereditary factor XIII deficiency: Report of four families and definition of the carrier state. Br J Haematol 1984; 56: 495-505
• 5 Rasehe H. Blutgerinnungsfaktor XIII und Fibrinstahilisicrung. Klin Wochenschr 1975; 53: 1137-1145
• 6 Baer U. Klinische Aspekte bei Anwendung des FXIII. In: Symposium liber Gerinnungsfaktor XIII. Bruckner WL. ed Munich, Vienna, Baltimore: Urban & Schwarzenberg; 1983: 105-116
• 7 McDonagh J. Structure and function of factor XIII. In: Hemostasis and thrombosis. Basic principles and clinical practice. Colman RW, Hirsh J, Marder VJ, Salzman EW. eds 2. nd Edn Philadelphia: JB Lippincott Co; 1987: 289-300
• 8 Miloszewski KJ A, Losowsky MS. Fibrin stabilisation and factor XIII deficiency. In: Fibrinogen, Fibrin Stabilisation and Fibrinolysis. Francis JL. ed Chichester: Ellis Horwood Ltd; 1988: 175-202
• 9 Kröniger A, Egbring R. Long-term treatment (12 years) with factor XIII concentrate in a patient with congenital factor XIII deficiency. In: Factor XIII and Fibronectin. Egbring R, Klingemann HG. eds Marburg: Medizinische Verlagsgesellschaft; 1983: 41-44
• 10 Hilfenhaus J, Weidmann E. Pasteurization as an efficient method to inactivate blood borne viruses in Factor XIII concentrates. Arzneimittel-forschung 1986; 36 (04) 621-625
• 11 Hilfenhaus J, Mauler R, Friis R, Bauer H. Safety of human blood products: Inactivation of retrovirusus by heart treatment at 60° C (42045). Proc Soc Exp Biol Med 1985; 178: 580-584
• 12 Dati F, Barthels M, Keller F. Determination of Coagulation Factor FXIII by a new Photometric Method. Abstract No. 0194 43rd National Meeting of the American Association for Clinical Chemistry; Washington D. C: 28.07.1991
• 13 Fickenscher K, Aab A, Stiiber W. A photometric assay for blood coagulation Factor XIII. Thromb Haemost 1991; 65 (05) 535-540
• 14 Gibaldi M, Perrier D. Pharmacokinetics. New York: Basel: Marcel Dekker; 1982: 445-449
• 15 Jones B, Kenward MG. Design and Analysis of Cross-Over Trials. New York: Chapman and Hall Ltd; 1989
• 16 Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinetics Biopharm 1987; 15 (06) 657-80
• 17 Zimmermann R, Ehlers W, Manz F, Meinrenken W, Egbring R, Gemmeke H. Ein neuer Fall von schwerem Faktor XIII-Mangel. Untersuehungen zum Verhalten der Untereinheiten und des Turnover des fibrinstabilisierenden Faktors Blut 1977; 35: 457-464